Inhibition of tumor growth and vasculogenic mimicry by cucumin through downregulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model

Cancer Biology and Therapy

Volumn 11, Issue 2, 2011, Pages 229-235

  Chen, Lu Xia ^a   He, Yan Jin ^a   Zhao, Shao Zhen ^a   Wu, Jian Guo ^a   Wang, Jian Tao ^a   Zhu, Li Min ^a   Lin, Ting Ting ^a   Sun, Bao Cun ^a,b   Li, Xiao Rong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Choroidal melanoma; Curcumin; Endothelium dependent vessels; EphA2; PI3K; Tumor growth; Vasculogenic mimicry

Indexed keywords

CURCUMIN; EPHRIN RECEPTOR A2; GELATINASE A; GELATINASE B; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHOROID MELANOMA; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; CHOROID NEOPLASMS; CURCUMIN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PERIODIC ACID-SCHIFF REACTION; PHOSPHATIDYLINOSITOL 3-KINASE; RANDOM ALLOCATION; RECEPTOR, EPHA2; RNA, MESSENGER; TUMOR BURDEN;

EID: 78751487154     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.2.13842     Document Type: Article

References (32)

1. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005; 18:75-84; PMID: 15763193.
2. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-52; PMID: 10487832.
3. Yue WY, Chen ZP. Vasculogenic mimicry-potential target for tumor therapy. Ai Zheng 2006; 25:914-6; PMID: 16831290.
4. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002; 62:560-6; PMID: 11809710.
5. Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-Kinase regulates membrane type1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003; 63:4757-62; PMID: 12941789.
6. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2) Cancer Res 2001; 61:3250-5; PMID: 11309274.
7. Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006; 16:693-8; PMID: 16969481.
8. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004; 190:899-909; PMID: 15118611.
9. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29:405-34; PMID: 20737283.
10. Sharma RA, McLell HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7:1894-900; PMID: 11448902.
11. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595:71-5; PMID: 17569205.
12. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 2008; 14:6228-36; PMID: 18829502.
13. Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vené R, et al. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007; 19:137-52; PMID: 17310108.
14. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmaco 2006; 71:1397-421; PMID: 16563357.
15. Getmanova EV, Chen Y, Bloom L, Shamah S, Warikoo V, Wang J, et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 2006; 13:549-56; PMID: 16720276.
16. Matsuda KM, Madoiwa S, Hasumi Y, Kanazawa T, Saga Y, Kume A, et al. A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene Ther 2000; 7:589-96; PMID: 10811477.
17. Zhang S, Zhang D, Wang Y, Zhao W, Guo H, Zhao X, et al. Morphologic research of microcirculation patterns in human and animal melanoma. Med Oncol 2006; 23:403-9; PMID: 17018898.
18. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin5gamma2 chain, matrix metalloproteinase-2 and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61:6322-7; PMID: 11522618.
19. Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y, et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exper Clin Cancer Res 2008; 27:60-9; PMID: 18983651.
20. Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu Y, et al. Doxycycline influences microcirculation patterns in B16 melanoma. Exp Biol Med 2007; 232:1300-7; PMID: 17959842.
21. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion angiogenesis and metastasis. Trends Cell Biol 2001; 11:37-43; PMID: 11684441.
22. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000; 2:62-9; PMID: 10655584.
23. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 2008; 27:2943; PMID: 18059341.
24. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). J Nutr Biochem 2003; 14:426-51; PMID: 12948874.
25. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005; 4:71-8; PMID: 15688074.
26. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasulogenic mimicry. Crit Rev Oncol 2002; 44:17-27; PMID: 12398997.
27. Mueller AJ, Maniotis AJ, Freeman WR, Bartsch DU, Schaller UC, Bergeron-Lynn G, et al. An orthotopic model for human uveal melanoma in SCID mice. Microvasc Res 2002; 64:207-13; PMID: 12204644.
28. Chen L, Zhang S, Li X, Sun B, Zhao X, Zhang D, et al. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. Oncol Rep 2009; 21:989-94; PMID: 19287998.
29. Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, et al. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008; 39:444-51; PMID: 18261629.
30. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 2008; 39:377-85; PMID: 18187184.
31. Chen L, Sun B, Zhang S, Zhao X, He Y, Zhao S, et al. Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma. Oncol Rep 2009; 21:917-23; PMID: 19287989.
32. Schostak M, Krause H, Miller K, Schrader M, Weikert S, Christoph F, et al. Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer. BMC Urol 2006; 15:1-7; PMID: 16539730.